Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TARGET THERAPEUTICS FASTRACKER HELPS SALES SPEED AHEAD 25.7% TO $35.4 MIL. IN FISCAL 1994; SUNRISE MEDICAL THIRD QUARTER SALES INCREASE 48.2%

This article was originally published in The Gray Sheet

Executive Summary

"Strong" domestic and international acceptance of Target Therapeutics products introduced since the beginning of its fiscal year helped revenues gain by 25.7% for the year (ended March 31) to $35.4 mil. "The FasTracker products, especially, have achieved a high degree of acceptance in a relatively short time," noted President and CEO Gary Bang.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT002315

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel